Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.55 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26348694 | 0.91 | GLP1R (0.66) | GLP1RLPAR3TLR2LPAR1 | |
| SCHEMBL24891111 | 0.84 | GLP1R (0.63) | GLP1RNMT2NMT1 | |
| SCHEMBL13184776 | 0.82 | GLP1R (0.54) | GLP1RNMT2NMT1FOLH1 | |
| SCHEMBL14998213 | 0.82 | GLP1R (0.57) | GLP1RNMT2NMT1LPAR3LPAR1 | |
| SCHEMBL13184781 | 0.81 | GLP1R (0.53) | GLP1RNMT2NMT1 | |
| SCHEMBL12660092 | 0.81 | GLP1R (0.61) | GLP1RFOLH1 | |
| SCHEMBL18552076 | 0.80 | GLP1R (0.75) | GLP1RLPAR3TLR2LPAR1 | |
| SCHEMBL27410264 | 0.80 | GLP1R (0.52) | GLP1RNMT2NMT1FOLH1 | |
| SCHEMBL12673878 | 0.80 | GLP1R (0.52) | GLP1RFOLH1 | |
| SCHEMBL19723974 | 0.79 | GLP1R (0.74) | GLP1RLPAR3TLR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GLP1R 319/4885NMT2 1805/4885NMT1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.